ZC2HC1A

Across TCGA pan-cancer cohorts, ZC2HC1A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZC2HC1A data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZC2HC1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZC2HC1A expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where ZC2HC1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.199	0.535	<.001	41	view →
UCEC	OS	Median	III,IV	0.494	1.000	.016	22	view →
CCRCC	DFS	Quartile	II,III,IV	0.819	1.000	.036	5	view →
LSCC	DFS	Tertile	All	1.000	0.913	.003	4	view →
GBM	DFS	Median	All	0.829	0.663	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZC2HC1A–PDAC (DFS)

Open the PDAC breakdown →